// App-Quantinova.ai

: Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Researchers

Presenter

  • Gilles Andre Salles

Principal Investigators

  • Wojciech Jurczak

  • David J. Andorsky

  • Donald P. Quick

  • Jack W. Singer

  • Simran Bedi Singh

  • Lixia Wang

  • Anton Egorov

  • Christine Gabarroca

  • Ruth Pettengell

Medical Centers

  • Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France

  • Jagiellonian University, Krakow, Poland

  • Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO

  • Joe Arrington Cancer Research and Treatment Center, Lubbock, TX

  • CTI BioPharma, Seattle, WA.

  • CTI BioPharma Corporation, Seattle, WA

  • Institut de Recherches Internationales Servier, Suresnes, France

  • Guy's Hospital, London, United Kingdom

Locations

  • France

  • Poland

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Diffuse large B-cell lymphoma

  • B-Cell Non-Hodgkin Lymphoma

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Pixantrone

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved